



TB in Your Practice: Focus on Co-Morbidities

CTCA ANNUAL CONFERENCE

May 5 - 6, 2010

Long Beach Hilton

Long Beach, CA

DRAFT AGENDA

Wednesday, May 5

- 8:30 - 10:00 am **Registration, Breakfast, Posters, Vendors**
- 10:00 am - 3:45 pm **Annual Business Meeting** (formerly TB Controllers Meeting) (open to all) -
Moderator: Ken Bird, MD, Fresno County (see separate agenda)
- 12:00 - 12:30 pm Working **Lunch** (Hosted)
- 2:00 - 5:00 pm **Nursing and Allied Health Professionals Forum** (open to all)
Business Meeting - Co-Moderators: Karen Redwine, RN, PHN, Alameda County;
Barbara Gregory, PHN, Berkeley
Workplace Contact Investigations - Moderator: Leslie Henry, RN, PHN, TBCB,
CDPH; speakers: Deborah Gold and Rachel Roisman, Occupational Health
Branch, CDPH; Tambi Shaw, TBCB, CDPH; Eleanor Ubina, Orange Co (see
separate agenda)
- 3:45 - 4:00 pm **Break, Posters, Vendors**
- 4:00 - 5:15 pm **Case/radiograph Presentations** - Moderator: Helene Calvet, MD, Long Beach
- 5:15 - 6:00 pm **Short Presentations**

Thursday, May 6

- 7:30 - 9:00 am **Registration, Breakfast, Posters, Vendors**
- 8:00 - 8:45 am **Corrections Meeting** - Co-Moderators: Marti Brentnall, TBCB, CDPH; Janet
Mohle-Boetani, MD, CA Department of Corrections (see separate agenda)
- 9:00 - 9:15 am **Welcome Ceremony** - Helene Calvet, MD, Health Officer, Long Beach



- 9:15 - 10:15 am **Jayne Ash Keynote Address - “TB in Your Practice: Focus on Co-Morbidities”** - Gisela Schecter, MD, MPH, Tuberculosis Control Branch, California Department of Public Health
1. Increase the utilization of TST or IGRA among diabetic patients with risk factors for LTBI.
 2. Encourage TB patients who smoke to discontinue smoking
 3. Screen all ESRD patients and patients on TNF-alpha antagonists for LTBI
 4. Extend treatment for diabetic patients when appropriate.
- 10:15 - 10:45 am **Break, Posters, Vendors**
- 10:45 - 11:30 am **Tuberculosis in the Era of Anti-Tumor Necrosis Factor (TNF) Therapy: Have We Dealt with the Problem?"** - Kevin Winthrop, MD, Oregon Health Sciences University
1. Recognize the types of biologic therapies typically used to treat rheumatic and other inflammatory diseases, and be able to discuss the risks for tuberculosis of these therapies with their patients and colleagues.
 2. Understand the utility of IGRAs in screening rheumatic disease patients for LTBI prior to anti-TNF therapy
 3. Understand the clinical presentations and management of TB in patients who are using anti-TNF therapies
- 11:30 am - 12:15 pm **How Do Co-Morbid Conditions Influence TB Care in CA?** - Jennifer Flood, MD, MPH, Tuberculosis Control Branch, California Department of Public Health
1. Describe what is known about the frequency of specific co-morbidities among persons with active TB and LTBI in California.
 2. Describe the types of providers caring for TB cases overall and for TB cases with specific co-morbidities.
 3. Describe opportunities for case detection, prevention and optimal management of TB among persons with co-morbidities.
- 12:30 - 1:45 pm **Awards Lunch (Hosted)** - Moderator: Richard Tezak, MD, Monterey County President’s Report
Outgoing Executive Committee Awards
Andy Lopez Award
Private Provider Award
Honorary Memberships
Henry Renteln Award
- 2:00 - 3:30 pm **Breakout Sessions**
- A. **Public - Private Partnerships at the Local Level (Panel)** - Tara Greenhow, MD, Kaiser Permanente Oakland; Myrna Mesrobian, MD, Los Angeles County; Yossef Aelony, MD, FACP, FCCP, Los Angeles County
1. Describe lessons learned from public-private sector collaboration in TB control efforts.
 2. Implement best practice models for public-private partnerships promoting TB control and prevention at the local level.



- B. **New Technologies for Rapid Diagnosis of MDR TB: Lab and Clinical Perspective** - Grace Lin, Microbial Diseases Laboratory, California Department of Public Health; Gisela Schechter, MD, MPH, TB Control Branch, California Department of Public Health
1. Request molecular screening for MDR TB appropriately when patients are at high risk of MDR TB.
 2. Appropriately request CDC service for molecular detection of drug resistance (1st line and 2nd-line drugs) for MDR TB cases or patients at high risk of MDR TB.
 3. Tailor anti TB treatment based on results of molecular assays.
- C. **TB and Diabetes: Challenges of Co-Management** - Christine Ho, MD, University of California San Francisco; Margaret Wheeler, MD, University of California San Francisco
- D. **LTBI Treatment, Surveillance for its Adverse Effects** - Moderator: John Jereb, MD, Division of Tuberculosis Elimination, Centers for Disease Control; speakers: Tom Navin, Division of Tuberculosis Elimination, Centers for Disease Control; Helene Calvet, MD, Long Beach; (3rd speaker TBA)
1. Report severe adverse effects associated with LTBI treatment to their corresponding public health authority for inclusion in national surveillance
 2. Select LTBI treatment candidates who have a favorable risk-benefit ratio
 3. Monitor for treatment adverse effects in accordance with California or national guidance and reduce adverse outcomes from adverse effects

3:30 - 4:00 pm

Break, Posters, Vendors

4:00 - 5:30 pm

Breakout Sessions (repeated)